Views & Analysis

Market Access
Addressing Europe’s plasma deficit

Addressing Europe’s plasma deficit

Across the European Union approximately 300,000 patients with chronic conditions, such as haemophilia and severe immune-deficiency, depend on plasma-derived medicines, which can only be man

Market Access
coins

Big pharma is slimming down

The last few years have been marked by many big pharma companies opting to move away from diversification and towards more focused operations.

Market Access
12 questions with: Daniel Kohlstaedt

12 questions with: Daniel Kohlstaedt

Daniel Kohlstaedt, managing director of PurpleLeaf Strategy, with more than 18 years of experience in pharma, talks about his journey through the industry.